Table 1.

Characteristics of S. enterica serovar Kentucky isolates from the French National Reference Center collection, 1959 to 1999

Strain	Yr of isolation	Source	Country of origin	Antimicrobial resistance profilea	PFGE typeb	MLST typec	SGI1
98K	1937	Chicken	USA	Susceptible	X4	ST198	Absence
2-59	1959	Human	Tunisia	Susceptible	NT	ST728	Absence
3-59	1959	Human	Angola	Susceptible	NT	ST152	Absence
1-61	1961	Human	Senegal	Susceptible	X1d	ST198	Absence
1-63	1963	Human	Vietnam	Susceptible	X19	ST198	Absence
2-64	1964	Fish meal	Portugal	Susceptible	X6	ST152	Absence
1-66	1966	Human	Vietnam	AMX	X18	ST198	Absence
1-67	1967	Fish meal	Portugal	Susceptible	NT	ST152	Absence
1-68	1968	Human	Senegal	STR SMX	X1b	ST727	Absence
61-69	1969	Turkey	France	TET	X2a	ST198	Absence
6-71	1971	Human	Tahiti (French Polynesia)	Susceptible	NT	ST152	Absence
14-72	1972	Human	Martinique (French West Indies)	Susceptible	X16	ST198	Absence
2-75	1975	Human	Senegal	Susceptible	X1a	ST198	Absence
3-75	1975	Human	Djibouti	Susceptible	X11	ST723	Absence
5-76	1976	Soya bean	France	Susceptible	X4	ST198	Absence
8-76	1976	Superficial water	Indonesia	STR	NT	ST198	Absence
9-76	1976	Meat flour	France	Susceptible	X9	ST198	Absence
4-77	1977	Poultry meal	France	STR	NT	ST198	Absence
12-78	1978	Fish meal	Turkey	STR	X15	ST198	Absence
18-78	1978	Human	Iraq	STR	X17	ST198	Absence
2-79	1979	Human	Guinea	Susceptible	X9	ST198	Absence
6-79	1979	Human	Burkina Faso	Susceptible	X9	ST724	Absence
4-82	1982	Human	Morocco	Susceptible	X20	ST393	Absence
1-83	1983	Human	Gabon	Susceptible	X12	ST198	Absence
8-84	1984	Human	Ivory Coast	Susceptible	X9	ST724	Absence
17-85	1985	Human	Egypt	STR SMX	X14	ST198	Absence
19-85	1985	Meat	Egypt	STR SPE CHL SMX TET	X2b	ST198	SGI1-J6
1-86	1986	Human	Vietnam	STR SPE CHL SMX TET	X2b	ST198	SGI1-J6
7-89	1989	Human	Ivory Coast	Susceptible	NT	ST696	Absence
12-89	1989	Human	Thailand	STR SPE CHL SMX TET	X2b	ST198	SGI1-J6
4-90	1990	Human	Israel	STR SPE CHL SMX TET	X2a	ST198	Absence
10-90	1990	Human	Indonesia	SMX	X2d	ST198	SGI1-J4
92-6276	1992	Human	Indonesia	STR SPE CHL SMX TET	X2e	ST198	SGI1-J6
92-6923	1992	Human	India-Nepal	Susceptible	X2g	ST198	Absence
93-6429	1993	Human	Indonesia	SMX	X2c	ST198	SGI1-J4
93-10205	1993	Human	Réunion Islande	Susceptible	X12	ND	Absence
94-1725	1994	Human	Senegal	AMP SUL	X1a	ND	Absence
94-3543	1994	Human	East Africa	Susceptible	X1c	ND	Absence
94-7021	1994	Human	India	Susceptible	X2h	ST198	Absence
94-7842	1994	Human	India	Susceptible	X2a	ST198	Absence
94-9173	1994	Human	India	Susceptible	X2j	ST198	Absence
95-5335	1995	Human	Mauritania	Susceptible	X1c	ND	Absence
96-8196	1996	Human	Africa	Susceptible	X1a	ND	Absence
96-11313	1996	Human	Egypt	STR SPE GEN SMX TET	X1a	ST198	SGI1-Ks
97-0568	1997	Human	Africa	STR SMX TMP	X1a	ND	Absence
97-2801	1997	Human	Tunisia	Susceptible	X8	ND	Absence
97-2858	1997	Human	Tunisia	Susceptible	X20	ST393	Absence
97-6819	1997	Human	Egypt	AMX STR SPE SMX TET	X1a	ST198	SGI1-Ks
97-11473	1997	Human	Egypt	AMX STR SPE GEN SMX TET NAL	X1k	ST198	SGI1-Ks
99-2998	1999	Human	Egypt	AMX CRO CAZ FOX STR CHL SMX TMP TET NALd	X1d	ND	Absence

^aAMX, amoxicillin; CRO, ceftriaxone; CAZ, ceftazidime; FOX, cefoxitin; CHL, chloramphenicol; GEN, gentamicin; KAN, kanamycin; SPE, spectinomycin; NAL, nalidixic acid; STR, streptomycin; SMX, sulfamethoxazole; TET, tetracycline; and TMP, trimethoprim. Bold antibiotic resistances are conferred by SGI1.

^bNT, not typeable due to lysis.

^cND, not done.

^dThis strain contains a bla_CMY-2 gene carried by an IncA/C 150-kb plasmid.

^eFrench territory in the Indian Ocean.